We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Lupus alpha Asset Management AG: Sensyne Health PLC

13 Apr 2022 17:00

Lupus alpha Asset Management AG (-) 13-Apr-2022 / 18:00 CET/CEST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Lupus alpha Asset Management AG

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

 The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

 Use a separate form for each offeror/offeree

Sensyne Health PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

 For an opening position disclosure, state the latest practicable date prior to the disclosure

08.04.2022

(in addition Lupus alpha Asset Management AG has dealt on previous dates during the offer period as attached at the end of this form).

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

 If it is a cash offer or possible cash offer, state "N/A"

N/A

If YES, specify which:

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary shares

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

 TOTAL:

0

0.00

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary shares

 

Sale

1,400,000

500,000

300,000

0.0219 GBP

0.0219 GBP

0.0219 GBP

Ordinary shares

Sale

290.000

0.0219 GBP

 

Lupus alpha Asset Management AG did not have discretion regarding voting decisions in respect of 290,000 shares that were sold on 08/04/2022 of which 70.000 shares were purchased on 09/11/2021

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

13.04.2022

Contact name:

Davor Dubovina

Telephone number*:

004969 36 50 58 7264

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

Purchases and sales

 

Date

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

09.11.2021

 

Ordinary shares

Purchase

490,000

70,000

0.9876 GBP

0.9876 GBP

09.11.2021

 

Ordinary shares

Purchase

70.000

0.9876 GBP

10.11.2021

 

Ordinary shares

Purchase

 

 

500,000

 

0.99 GBP

             

 

 

 


Category Code:RET - Sensyne Health PLC
TIDM:-
LEI Code:529900JRIM4CXFEUZK50
Sequence No.:155546
EQS News ID:1327507
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
20th Jun 20227:00 amRNSCancellation - Sensyne Health plc
17th Jun 20224:41 pmRNSSecond Price Monitoring Extn
17th Jun 20224:36 pmRNSPrice Monitoring Extension
15th Jun 20226:00 pmRNSSensyne Health
15th Jun 202211:00 amRNSPrice Monitoring Extension
14th Jun 20222:05 pmRNSSecond Price Monitoring Extn
14th Jun 20222:00 pmRNSPrice Monitoring Extension
14th Jun 202211:05 amRNSSecond Price Monitoring Extn
14th Jun 202211:00 amRNSPrice Monitoring Extension
14th Jun 20229:00 amRNSPrice Monitoring Extension
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
6th Jun 202212:46 pmRNSResults of General Meeting
19th May 202211:05 amRNSSecond Price Monitoring Extn
19th May 202211:00 amRNSPrice Monitoring Extension
18th May 20225:12 pmRNSPublication of circular, notice of general meeting
17th May 20222:06 pmRNSSecond Price Monitoring Extn
17th May 20222:00 pmRNSPrice Monitoring Extension
3rd May 20223:24 pmRNSHolding(s) in Company
28th Apr 20224:40 pmRNSSecond Price Monitoring Extn
28th Apr 20224:35 pmRNSPrice Monitoring Extension
21st Apr 20222:05 pmRNSSecond Price Monitoring Extn
21st Apr 20222:00 pmRNSPrice Monitoring Extension
19th Apr 202212:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
19th Apr 202211:05 amRNSSecond Price Monitoring Extn
19th Apr 202211:00 amRNSPrice Monitoring Extension
19th Apr 20229:53 amRNSForm 8.3 - Sensyne Health Plc
19th Apr 20228:54 amRNSForm 8.5 (EPT/RI)
19th Apr 20227:00 amRNSAmendments to Financing
14th Apr 202212:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
14th Apr 20229:21 amRNSForm 8.5 (EPT/RI) - Sensyne Health PLC
13th Apr 20225:00 pmEQSForm 8.3 - Lupus alpha Asset Management AG: Sensyne Health PLC
13th Apr 202212:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
13th Apr 20229:27 amRNSForm 8.5 (EPT/RI)
12th Apr 202212:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
12th Apr 20228:31 amRNSForm 8.5 (EPT/RI)
12th Apr 20227:00 amRNSHoldings in Company
11th Apr 20222:00 pmRNSPrice Monitoring Extension
11th Apr 20221:36 pmRNSForm 8.3 - Sensyne Health plc
11th Apr 202212:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
11th Apr 202210:34 amRNSForm 8.3 - Sensyne Health plc
11th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - Sensyne Health PLC
11th Apr 20229:07 amRNSForm 8.3 - Sensyne Health Plc
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:35 pmRNSPrice Monitoring Extension
8th Apr 202212:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
8th Apr 20229:05 amRNSSecond Price Monitoring Extn
8th Apr 20229:00 amRNSPrice Monitoring Extension
8th Apr 20227:00 amRNSBoard Change and Updates on Financing and FSP
7th Apr 20221:23 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.